2017
DOI: 10.1111/jdv.14361
|View full text |Cite
|
Sign up to set email alerts
|

Giant orf tumour in an immunocompromised patient

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
5
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(5 citation statements)
references
References 6 publications
0
5
0
Order By: Relevance
“…The antiviral, antiproliferative, and antiangiogenic properties of systemic interferon alfa-2a result in complete regression of the lesions, making it a suitable option for treatment of recalcitrant giant orf in immunocompromised patients. [13][14][15][16][17] In conclusion, immunocompromised patients may experience giant, persistent, and atypical lesions of orf disease. Our case highlights the importance of considering orf as a differential diagnosis, especially in immunocompromised patients complaining of a nodule or tumor-like lesions with a past history of close contact with animals such as sheep and goats or a history of cutting a body part through meat cleaning.…”
Section: Discussionmentioning
confidence: 96%
See 1 more Smart Citation
“…The antiviral, antiproliferative, and antiangiogenic properties of systemic interferon alfa-2a result in complete regression of the lesions, making it a suitable option for treatment of recalcitrant giant orf in immunocompromised patients. [13][14][15][16][17] In conclusion, immunocompromised patients may experience giant, persistent, and atypical lesions of orf disease. Our case highlights the importance of considering orf as a differential diagnosis, especially in immunocompromised patients complaining of a nodule or tumor-like lesions with a past history of close contact with animals such as sheep and goats or a history of cutting a body part through meat cleaning.…”
Section: Discussionmentioning
confidence: 96%
“…The antiviral, antiproliferative, and antiangiogenic properties of systemic interferon alfa‐2a result in complete regression of the lesions, making it a suitable option for treatment of recalcitrant giant orf in immunocompromised patients. 13 , 14 , 15 , 16 , 17 …”
Section: Discussionmentioning
confidence: 99%
“…The main hosts are small ruminants, but the virus can readily infect broken skin of humans in close contact with diseased animals. The self‐limiting, benign disease resolves after several weeks, but in immunocompromised or young individuals, severe complications, such as secondary bacterial infections or “Giant Orf,” can occur . A pustular dermatitis with a mixed inflammatory infiltrate and hyperproliferation of keratinocytes are the main features of infection in animals and humans …”
Section: Introductionmentioning
confidence: 99%
“…The self-limiting, benign disease resolves after several weeks, but in immunocompromised or young individuals, severe complications, such as secondary bacterial infections or "Giant Orf," can occur. [5][6][7][8] A pustular dermatitis with a mixed inflammatory infiltrate and hyperproliferation of keratinocytes are the main features of infection in animals and humans. [8,9] This study identifies human primary keratinocytes (KC) and human primary dermal fibroblasts (FB) as susceptible for ORFV infection, however, with limited support for viral replication.…”
mentioning
confidence: 99%
“…However, it is well known that contagious ecthyma can trigger erythema multiforme (8). The disease is self-limiting and therefore does not usually require specific treatment (9-11), although there are several different treatment options, including cryotherapy, imiquimod, acyclovir and intralesional interferon injections (12)(13)(14). Local antiseptic treatment, however, is recommended to prevent bacterial super-infection.…”
mentioning
confidence: 99%